| Top 5 Stories : |
|
"Sunshine" Goes Live — Despite Incomplete Information
While the federal Open Payments program went live September 30—albeit with 40% of the reported data de-identified—biopharma companies continue to be concerned about the lack of context provided for the payment information, and minimal explanation of how relationships between industry and physicians are not always illicit.
Read more
|
|
|
How the "Millennials" Demographic is Shaping US Healthcare
For the first time in decades, the 18-to-34 year-old set now claims the largest share (23.5%) of the US population, giving them the clout to color the conduct of basic business practices like marketing, reputation and customer engagement. With so much at stake, where can the industry make a difference in catering to this younger demographic?
Read more
|
|
|
IDEAlogue for Innovation: A Conversation with Italy's Fabio Pammolli
Pharm Exec sat down with Fabio Pammolli, a 48-year-old Italian economist selected by the European Commission as the first author/convener of a set of critical overviews on the state of the industry, from a national, regional and global perspective, to get his perspective on the state of drug innovation within European industry.
Read more
|
|
|
The Place of Digital in the Pharma Marketing Mix
Yes, digital is the future of marketing. But brands and the people that use them don't live in the future— they live now, and if our median audience member is more than 50 years old, it would be foolish for the center of gravity of our marketing mix to lie on the digital side of the scale.
Read more
|
|
|
The "Value" of Rx's Under Obamacare
For the U.S. brand name drug industry, it's fair to say this first year of Obamacare has been a year with more than a little bit of confusion, a lot of uncertainty, and yes, some serious angst about how all the moving parts of Obamacare Rx program will actually impact the U.S. pharmaceutical business.
Read more
|
|
|
| Trending on Social Media : |
NIH Invests in Biomedical Big Data
The National Institutes of Health (NIH) announced that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.
Read more
|
Healthcare Nonprofit Bans Genentech Reps
After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension's 1900 sites of care around the country.
Read more
|
Email Marketing's Growing Maturity
The long-anticipated demise of email marketing looks further away than ever, with practitioners using data to make better decisions, developing sophisticated relationships with their customers and leaving email's spotty, spammy adolescence behind.
Read more
|
|
|
| Follow Us |
|
|
|
|
